{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T16:00:40Z","timestamp":1648569640766},"reference-count":45,"publisher":"Publicidad Permanyer, SLU","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Cardiolog\u00eda de M\u00e9xico"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.acmx.2018.01.003","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T11:35:06Z","timestamp":1519817706000},"page":"287-297","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Un novedoso agente en el tratamiento de la insuficiencia cardiaca con funci\u00f3n sist\u00f3lica deprimida"],"prefix":"10.24875","volume":"88","author":[{"given":"Yan C.","family":"Duarte Vera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia V.","family":"C\u00e1ceres Vinueza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Daher Nader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joffre F.","family":"Lara Ter\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10499","reference":[{"key":"10.1016\/j.acmx.2018.01.003_bib0230","first-page":"e1","volume":"69","author":"Ponikowski","year":"2016","journal-title":"Gu\u00eda ESC 2016 Sobre el diagn\u00f3stico y tratamiento de la insuficiencia cardiaca aguda y cr\u00f3nica."},{"key":"10.1016\/j.acmx.2018.01.003_bib0235","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA Guideline for the management of heart failure","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acmx.2018.01.003_bib0240","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acmx.2018.01.003_bib0245","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMcp0909392","article-title":"Systolic heart failure","volume":"362","author":"McMurray","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acmx.2018.01.003_bib0250","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med."},{"issue":"Suppl A","key":"10.1016\/j.acmx.2018.01.003_bib0255","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/eurheartj\/9.suppl_A.171","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure","volume":"9","author":"Cohn","year":"1988","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acmx.2018.01.003_bib0260","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acmx.2018.01.003_bib0265","doi-asserted-by":"crossref","unstructured":"CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian\u00a0Enalapril\u00a0Survival Study (CONSENSUS). N Engl J Med. 1987; 316:1429-35.","DOI":"10.1056\/NEJM198706043162301"},{"key":"10.1016\/j.acmx.2018.01.003_bib0455","doi-asserted-by":"crossref","unstructured":"The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.","DOI":"10.1056\/NEJM199108013250501"},{"key":"10.1016\/j.acmx.2018.01.003_bib0275","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMp1410241","article-title":"Paradigm shifts in heart-failure therapy \u2014 A timeline","volume":"371","author":"Sacks","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acmx.2018.01.003_bib0280","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acmx.2018.01.003_bib0460","doi-asserted-by":"crossref","unstructured":"CIBIS Investigators. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1990; 90(4):1765-73. DOI: 10.1161\/01.cir.90.4.1765.","DOI":"10.1161\/01.CIR.90.4.1765"},{"key":"10.1016\/j.acmx.2018.01.003_bib0465","doi-asserted-by":"crossref","unstructured":"CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353: 9-13. https:\/\/doi.org\/10.1016\/s0140-6736(98)11181-9.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"10.1016\/j.acmx.2018.01.003_bib0295","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","article-title":"Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III","volume":"112","author":"Willenheimer","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.acmx.2018.01.003_bib0300","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.acmx.2018.01.003_bib0470","doi-asserted-by":"crossref","unstructured":"Hjalmarson \u00c5, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA. 2000; 283(10):1295. https:\/\/doi.org\/10.1001\/jama.283.10.1295.","DOI":"10.1001\/jama.283.10.1295"},{"key":"10.1016\/j.acmx.2018.01.003_bib0475","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme W, et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. N Engl J Med. 1999; 341:709-17. https:\/\/doi.org\/10.1056\/nejm199909023411001.","DOI":"10.1056\/NEJM199909023411001"},{"key":"10.1016\/j.acmx.2018.01.003_bib0315","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s40265-013-0098-z","article-title":"Eplerenone: A review of its use in patients with chronic systolic heart failure and mild symptoms","volume":"73","author":"Dhillon","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.acmx.2018.01.003_bib0320","doi-asserted-by":"crossref","first-page":"A107","DOI":"10.1016\/0735-1097(93)90472-D","article-title":"Digoxin in heart failure: Implications of recent trials","volume":"22","author":"Kelly","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acmx.2018.01.003_bib0325","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/01.CIR.73.1.14","article-title":"Digitalis \u2014a new controversy regarding an old drug. The pitfalls of inappropriate methods","volume":"73","author":"Yusuf","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.acmx.2018.01.003_bib0330","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0002-9343(90)90154-6","article-title":"To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis","volume":"88","author":"Jaeschke","year":"1990","journal-title":"Am J Med."},{"key":"10.1016\/j.acmx.2018.01.003_bib0335","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"Perry","year":"1997","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acmx.2018.01.003_bib0340","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0167-5273(01)00600-3","article-title":"Current evidence supporting the role of diuretics in heart failure: A meta-analysis of randomized controlled trials","volume":"82","author":"Faris","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acmx.2018.01.003_bib0345","doi-asserted-by":"crossref","unstructured":"De Teresa E. Tratamiento diur\u00e9tico de la insuficiencia cardiaca. Rev Esp Cardiol Supl. 2007;7:34F-44F. https:\/\/doi.org\/10.1016\/s1131-3587(07)75254-8","DOI":"10.1016\/S1131-3587(07)75254-8"},{"key":"10.1016\/j.acmx.2018.01.003_bib0350","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjcard.2007.11.012","article-title":"Biology of the natriuretic peptides","volume":"101","author":"Martinez-Rumayor","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acmx.2018.01.003_bib0355","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.peptides.2004.09.024","article-title":"Biology of natriuretic peptides and their receptors","volume":"26","author":"Pandey","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.acmx.2018.01.003_bib0360","doi-asserted-by":"crossref","first-page":"66","DOI":"10.15420\/ECR.2005.66","article-title":"Natriuretic peptides\u2014A review","volume":"1","author":"Collinson","year":"2005","journal-title":"Eur Cardiol."},{"key":"10.1016\/j.acmx.2018.01.003_bib0365","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Epstein","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acmx.2018.01.003_bib0370","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acmx.2018.01.003_bib0375","series-title":"cGMP:Generators Effectors and Therapeutic Implications","first-page":"341","article-title":"Natriuretic peptides: Their structures, receptors, physiologic functions and therapeutic applications","author":"Potter","year":"2009"},{"key":"10.1016\/j.acmx.2018.01.003_bib0380","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMoa031994","article-title":"Plasma natriuretic peptide levels and the risk of cardiovascular events and death","volume":"350","author":"Wang","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acmx.2018.01.003_bib0385","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa042330","article-title":"N-terminal pro\u2013B-type natriuretic peptide and long-term mortality in stable coronary heart disease","volume":"352","author":"Kragelund","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acmx.2018.01.003_bib0390","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10554-007-9256-2","article-title":"The role of the N-terminal pro-brain natriuretic peptide in the evaluation of left ventricular diastolic dysfunction: correlation with echocardiographic indexes in hypertensive patients","volume":"24","author":"Ceyhan","year":"2007","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.acmx.2018.01.003_bib0395","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","article-title":"The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT","volume":"25","author":"Latini","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acmx.2018.01.003_bib0400","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11906-003-0045-6","article-title":"Recent clinical trials with omapatrilat: New developments","volume":"5","author":"Zanchi","year":"2003","journal-title":"Curr Hypertens Rep."},{"key":"10.1016\/j.acmx.2018.01.003_bib0405","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.acmx.2018.01.003_bib0410","first-page":"386","article-title":"Inhibici\u00f3n dual de la neprilisina y el receptor de angiotensina ii: nueva estrategia prometedora en el tratamiento de la enfermedad cardiovascular","volume":"20","author":"Manzur","year":"2013","journal-title":"Rev Colomb Cardiol"},{"key":"10.1016\/j.acmx.2018.01.003_bib0415","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin Inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acmx.2018.01.003_bib0420","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1-2","key":"10.1016\/j.acmx.2018.01.003_bib0425","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2012.03.005","article-title":"Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction","volume":"378","author":"Jing","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.acmx.2018.01.003_bib0430","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00125-016-4172-4","article-title":"Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels","volume":"60","author":"Willard","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.acmx.2018.01.003_bib0435","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.2337\/db13-0478","article-title":"NH2-terminal pro-brain natriuretic peptide and risk of diabetes","volume":"62","author":"Lazo","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.acmx.2018.01.003_bib0440","doi-asserted-by":"crossref","first-page":"e44782","DOI":"10.1371\/journal.pone.0044782","article-title":"Kinin B1 receptor in adipocytes regulates glucose tolerance and predisposition to obesity","volume":"7","author":"Mori","year":"2012","journal-title":"Plos ONE"},{"key":"10.1016\/j.acmx.2018.01.003_bib0445","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00125-005-1847-7","article-title":"Neutral endopeptidase 24.11 and dipeptidyl peptidase iv are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig","volume":"48","author":"Plamboeck","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.acmx.2018.01.003_bib0450","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/archinte.1996.00440160069010","article-title":"Angiotensin ii receptor inhibition","volume":"156","author":"Messerli","year":"1996","journal-title":"Arch Intern Med"}],"container-title":["Archivos de Cardiolog\u00eda de M\u00e9xico"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1405994018300041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1405994018300041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.archivoscardiologia.com\/previos\/(2018)%20ACM%20Vol%2088.%204%20OCTUBRE-DICIEMBRE\/ACMX_2018_88_4_287-297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T11:05:00Z","timestamp":1561979100000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.archivoscardiologia.com\/previos\/(2018)%20ACM%20Vol%2088.%204%20OCTUBRE-DICIEMBRE\/ACMX_2018_88_4_287-297.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1405994018300041"],"URL":"https:\/\/doi.org\/10.1016\/j.acmx.2018.01.003","relation":{},"ISSN":["1405-9940"],"issn-type":[{"value":"1405-9940","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Un novedoso agente en el tratamiento de la insuficiencia cardiaca con funci\u00f3n sist\u00f3lica deprimida","name":"articletitle","label":"Article Title"},{"value":"Archivos de Cardiolog\u00eda de M\u00e9xico","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acmx.2018.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez. Published by Masson Doyma M\u00e9xico S.A.","name":"copyright","label":"Copyright"}]}}